id="ulink_88e47617-d7e4-511f-af42-11e14b497325">[185] Moloney A, Turnbridge WMG, Ireland JT, Watkins PJ. Mortality from diabetic nephropathy in the United Kingdom. Diabetologia 1983; 25: 26-30.
[186] Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 29: 230-3.
[187] Matthiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884-6.
[188] Brunner FP, Selwood NH. Profile of patient on RRT in Europe and death rate due to major causes of death groups. The EDTA Registration Committee. Kidney Int 1992; 38 (suppl): S4-15.
[189] Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/ creatinine ratio. J Am Soc Nephrol 1996; 7: 930-7.
[190] Ravid M, Savin H, Jutin I, Bental T, Lang R, Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994; 45 (suppl): S161-164.
[191] Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-4.
[192] Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-5.
[193] Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH. Is diabetic nephropathy an inherited complication ? Kidney Int 1992; 41: 719-22.
[194] Toeller M, Buyken A, Heitkamp G, Brämswig S, Man J, Milne R, Gries FA, Keen H, and the EURODIAB IDDM Complications Study Group. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997; 40: 1219-26.
[195] Mogensen CE. Natural history of renal functional abnormalities in human diabetes mellitus: from normoalbuminuria to incipient and overt nephropathy. In: Brenner BM, Stein JH, editors. The kidney in diabetes mellitus. New York: Churchill Livingstone; 1989: 19-49.
[196] Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38: 1077-81.
[197] Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences and prevention. Diabetologia 1992; 35: 803-12.
[198] Osterby R, Gall MA, Schmitz A, Nielsen FS, Nyberg G, Parving HH. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients, Diabetologia 1993; 36: 1064-70.
[199] Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993; 341: 1306-9.
[200] Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuria type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1051-6.
[201] Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartman A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-90.
[202] Sawicki PT. Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. Diabetes Treatment and Teaching Programmes Working Group. Nephrol Dial Transplant 1997; 12: 1890-9.
[203] European Diabetes Policy Croup. A desktop guide to type 2 diabetes mellitus. Diabetic Med 1999; 16: 716-30.
[204] American Diabetes Association. Diabetic nephropathy. Diabetes Care 2000; 23 (suppl 1): S67-72.
[205] EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.
[206] UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes, UKPDS 39. BMJ 1998; 317: 713-20.
[207] Marre MJ, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-5.
[208] Microalbuminuria Captopril Study Group. Captopril reduced the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-93.
[209] Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, Nakayama M, Hara T, Matsuo S, Sakamoto N. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med 1996; 13: 120-4.
[210] Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-81.
[211] Jungmann E, Haak T, Malanyn M, Mortasawi N, Unterstöger E, Scherberich J, Usadel KH: Vergleichsstudie zur Wirkung von Nitrendipin und Enalapril auf Mikroalbuminuria und Alpha-1-Mikroglobulin-Ausscheidung bei Patienten mit Typ 1 Diabetes mellitus. Diabetes Stoffw 1993; 2: 372-7.
[212] Crepaldi G, Casta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa MG, Nosadini R. The Italian Microalbuminuria Study Group in IDDM: Effect of lisinopril and nifedepine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104-10.
[213] Bjorck S, Mulec H, Johnson SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43.
[214] Lewis EJ, Hunsicker LG, Bani RP, Rhode RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Collab Study Group. N Engl J Med 1993; 329: 1456-62.
[215] Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81.
[216] Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotension-converting-enzyme inhibition on diabetic nephropathy. The Collaberative Study Group. Am J Med 1995; 99: 497-504.
[217] Slataper R, Vicknair N, Sadler R, Bakris G. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973-80.
[218] Elving LD, Wetzels JFM, Lier HJJ van, Nobel E de, Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2 year prospective, randomized study. Diabetologia 1994; 37: 604-9.
[219] Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641-50.
[220] Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carrara A, Tonolo G, Tresu P, Cemigoi AM, Fioretto P, Nosadini R. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-22.
[221] Böhlen L, DeCourten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S-92S.
[222] Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and
